BuybackAug 11, 2026, 09:06 AM
Cardinal Health FY26 Revenue +14% to $254.2B; New $5B Buyback
AI Summary
Cardinal Health reported a strong fiscal year 2026 with revenue increasing 14% to $254.2 billion and non-GAAP diluted EPS rising 37% to $11.26. The company's Board of Directors approved a new $5.0 billion share repurchase program. Key drivers included the acquisition of Solaris Health for $1.9 billion and robust performance in its Pharmaceutical and Specialty Solutions segment, though results were partially offset by goodwill and equity impairments and ongoing tariff challenges.
Key Highlights
- Board approved a new $5.0 billion share repurchase program on August 4, 2026.
- Fiscal 2026 revenue increased 14% to $254.2 billion.
- Non-GAAP diluted EPS rose 37% to $11.26 in fiscal 2026.
- Acquired Solaris Health, a urology MSO, for approximately $1.9 billion in November 2025.
- Pharma segment profit grew 23% to $2.8 billion, driven by branded and specialty pharmaceuticals.
- GMPD segment profit increased 91% to $258 million, despite tariff impacts.
- Recognized a $184 million goodwill impairment charge and $122 million equity impairment in FY26.
- Paid $417 million related to opioid litigation in fiscal 2026, with $4.3 billion accrued.
Price Impact
More from CAH